Article

Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignancies

2025-09-04

Abstract excerpt

Relapsed and refractory T cell malignancies are associated with poor clinical outcomes. Autologous sources of αβT cells have been employed for chimeric antigen receptor (CAR) therapies to eliminate the potential for graft-vs-host disease (GvHD). However, the application of CAR-T therapy for T-ALL has been hindered by an inability to obtain sufficient healthy αβT cells from patients combined with fratricide due to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4c94f340-5b90-55c1-a486-0c7d5bb9bfa2
DOI: 10.1101/2025.08.30.673295

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignanciesDOI 10.1101/2025.08.30.673295Read

CD38‐Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK CellsSemantic proximity Read

Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for ‘off-the-shelf’ ImmunotherapySemantic proximity Read

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignanciesSemantic proximity Read

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemiaSemantic proximity Read

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read

Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapySemantic proximity Read

Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic EffectsSemantic proximity Read

A method for polyclonal antigen-specific T cell-targeted genome editing (TarGET) for adoptive cell therapy applicationsSemantic proximity Read

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cellsSemantic proximity Read

Comprehensive genome editing confers ‘off-the-shelf’ CAR-T cells superior efficacy against solid tumorsSemantic proximity Read

Next-generation all-in-one CRISPR/Cas9 multiply-edited CD30CAR-T cells: Potency despite risk of translocationsSemantic proximity Read

Targeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioningSemantic proximity Read